Phosphodiesterase 5 Inhibitor international drug patents, generic suppliers and generics

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-001	Dec 16, 2025		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-002	Dec 16, 2025		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-002	Dec 16, 2025		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 9, 2026

Phosphodiesterase-5 Inhibitors Market Dynamics and Patent Landscape: Exclusivity, Key Patents, and Generic Entry Risks Across Sildenafil, Tadalafil, Vardenafil, and Avanafil

Executive summary: The PDE5 inhibitor market is dominated by sildenafil, tadalafil, vardenafil, and avanafil, with mature patent estates in the major jurisdictions. Patent-driven dynamics now hinge on (1) late-expiring formulation and method-of-use patents, (2) protracted lifecycle litigation and patent settlements that shape launch timing, and (3) country-by-country Orange Book equivalents and exclusivity terms (notably US regulatory exclusivities and branded-device/combination constraints where applicable). For most markets, first-line generics are already established; incremental patent protection remains most relevant for newer dosage forms (eg, tadalafil once-daily formulations), specific clinical populations, and combination products rather than for the original active ingredients.

Which PDE5 inhibitors still have enforceable patents in 2026?

Featured snippet answer: Enforceable PDE5 IP coverage in 2026 typically resides in secondary patents covering formulation, dosing regimen, specific indications (method-of-use), and manufacturing processes, not the original active ingredient composition-of-matter for older brands. The principal active ingredients are generally off primary composition-of-matter in major markets, while the remaining enforceable rights vary by jurisdiction and by product line (dose strength, release profile, patient subgroups).

US enforcement tends to shift from composition to “device-formulation-method”

For PDE5 inhibitors, the patent estate pattern in the US is consistent:

Original composition-of-matter patents for sildenafil and tadalafil largely exhausted years earlier.
Later patents cover:
- specific crystalline forms or polymorphs,
- distinct film coatings or solid-state forms,
- dosing regimens (eg, once-daily dosing windows),
- combinations (less common across PDE5 agents but present for some branded packages),
- method-of-use for expanded indications (eg, specific comorbidities).

What to look for in country-level registers

US: Orange Book for approved NDA/ANDA products and listed patents tied to each NDA.
Europe: EP patent families and national validations; enforcement through unitary/national actions.
UK: patents and regulatory data exclusivity effects at the national level.
Canada/Japan: patent linkage practices and generic launch “utility” of register listings.

When do PDE5 inhibitor patents expire, and what is the last date for generic launch?

Featured snippet answer: For mature PDE5 inhibitors, the last-date-to-launch for generics is typically governed by the expiration of the newest listed patents for each brand product and by any stay agreements from ANDA litigation. The “hard” dates are patent expiry and any regulatory exclusivity; the “practical” dates are entry timing after settlements.

Market reality: generic entry already occurred for most active ingredients

By 2026:

sildenafil is broadly generic across most major markets
tadalafil is widely generic across most major markets
vardenafil and avanafil are also broadly generic, though market penetration differs by geography and reimbursement

The remaining entry risk: lifecycle patents attached to particular strengths or regimens

Even when the active ingredient is off-patent, generics can be blocked for:

a specific dosage strength (eg, a formulation-specific patent)
a specific release profile (immediate vs prolonged exposure)
a specific dosing regimen (eg, once-daily regimen claims that are not coextensive with earlier off-label uses)

US Paragraph IV-driven timing

In the US, generic launch dates are commonly delayed by:

Hatch-Waxman paragraph IV litigation
court-issued automatic stays (when the ANDA triggers them)
settlement agreements that set delayed launch windows

What patents protect sildenafil and what generic entry risks still exist?

Featured snippet answer: The sildenafil patent estate in major markets has largely shifted to lifecycle protections covering formulation/process and dosing regimen constructs. Generic entry risks persist only when an ANDA is designed to “carve out” around listed patents for a branded dosage form or specific use claim.

US patent landscape pattern for sildenafil

Sildenafil branded products (including erectile dysfunction and pulmonary hypertension legacy lines historically) typically show:

older composition-of-matter patents no longer a gating factor
newer patent lists (when present) tied to:
- formulation and solid-state properties
- dosing regimen claims
- certain method-of-use claims for expanded patient populations

Commercial dynamics that drive enforcement

sildenafil’s volume is high, so any delay produces significant commercial value
brand holders pursue enforcement selectively where patent listings map cleanly to a commercial bottleneck product

What patents protect tadalafil and why is the estate more complex for once-daily regimens?

Featured snippet answer: Tadalafil’s estate has recurring lifecycle layers because once-daily use and specific dosing regimens create patentable claim structures that do not mirror off-label generic dosing. The most relevant remaining risks are around once-daily formulation and method-of-use claims tied to patient management patterns.

Formulation and regimen claims are the key

Tadalafil’s patent protections historically included:

solid-state/formulation patents for specific tablets and release characteristics
regimen-related method-of-use claims (timing and dosing frequency)
process patents for manufacturing steps that support specific performance attributes

Why “regimen” matters for generic design

Even when generics can match bioequivalence, they may avoid infringement only by:

selecting a different route of dosing not covered by claims
using a formulation not protected by the listed patent claims
aligning labeling to avoid method-of-use infringement scenarios

What patents protect vardenafil, and how do patent estates differ versus sildenafil and tadalafil?

Featured snippet answer: Vardenafil’s remaining protection tends to be narrower and more geographically fragmented than tadalafil, with continued risk concentrated in dosage form and specific lifecycle patents rather than broad method-of-use coverage.

Lifecycle protection hotspots

film coating and tablet formulation patents
manufacturing/process patents
regimen-related method-of-use claims, where they exist in Orange Book-equivalent listings

Market entry implications

Because vardenafil competes against entrenched sildenafil/tadalafil pricing and formulary positioning, enforcement is often targeted to:

specific dose strengths with meaningful payer preference
regional markets where generics are slower to obtain or reimbursed

What patents protect avanafil, and is the estate still relevant to late-stage generics?

Featured snippet answer: Avanafil is generally newer than the earliest sildenafil/tadalafil entries, so lifecycle patents can remain more relevant for certain dosage forms and labeled regimens. However, its scale in many geographies still favors partial protection strategies rather than broad global injunction attempts.

Typical avanafil patent themes

formulation and manufacturing process patents for tablet performance
method-of-use claims for labeled ED management constructs
fewer combination/regimen layers relative to tadalafil’s once-daily commercial structure

How many patents cover PDE5 inhibitors in the Orange Book, and what does that imply for exclusivity?

Featured snippet answer: Patent-count is best interpreted product-by-product rather than class-wide. For each branded PDE5 NDA, the number of Orange Book-listed patents often includes multiple lifecycle categories, but only a subset are enforceable and “triggerable” against specific ANDAs.

How patent listings map to launch risk

Orange Book lists do not all block approval; only patents with a relevant claim to the ANDA product matter.
Multiple patents in one family can create layered litigation risk across different ANDA filers.

Practical enforcement strategy

Brand holders prioritize:

the newest patent in the chain that is still in force
patents most directly aligned with ANDA generic formulation and proposed label

Which companies are challenging PDE5 inhibitor patents via Paragraph IV ANDAs?

Featured snippet answer: Paragraph IV challenges for PDE5 inhibitors typically involve large generic companies and specialty filers who build “at-risk” launch plans around tailored claim-avoidance and label carve-outs. The overall pattern is that multiple ANDAs can be filed for a single branded product, creating a litigation matrix.

What litigation matrices generally look like

For each branded PDE5 product:

multiple ANDAs may certify non-infringement/invalidity against different listed patents
one or two patents often drive the most significant stay outcomes
settlements frequently set staggered launch windows aligned to each filer’s design and timing

(No specific company challenge list can be produced here without product-by-product Orange Book capture and litigation docket mapping.)

What does PDE5 inhibitor patent litigation look like in the US, and what settlement terms delay launches?

Featured snippet answer: PDE5 inhibitor patent litigation is often a sequence of early motion practice and settlement-driven launch schedules. Settlement terms typically focus on a date-certain delayed launch, with design-around provisions and mutual covenant structures.

Settlement structures common to class lifecycle

date-certain generic launch delay for specific strengths
carve-out for future formulations or additional dose strengths
“non-assert” covenants after the launch date for specified ANDA products
dismissal of claims paired with mutual consideration

Where stays matter most

if a settlement triggers a longer-than-expected delay, it usually reflects a broader view of relevant claims than the earliest list patent
if a settlement is short, it usually reflects narrow claim relevance or weak enforceability

What is the Orange Book status of sildenafil, tadalafil, vardenafil, and avanafil?

Featured snippet answer: Orange Book status is granular by NDA and dosage strength. The active ingredient in each class includes multiple approved branded products, each with potentially distinct patent listings and termination dates.

Status by product type

branded ED products: generally have older families long expired, with residual lifecycle listings in some dosage profiles
labeled alternative indications (where applicable historically): may have separate patent lines and more distinct timelines

(A class-level Orange Book status table requires product-specific Orange Book extraction, and cannot be accurately enumerated here.)

How does FDA exclusivity affect PDE5 inhibitor generic launches beyond patents?

Featured snippet answer: FDA exclusivity can extend “practical exclusivity” beyond patent expiry, but for established PDE5 inhibitors the more common effect is limited unless a newer NDA qualifies for a period of exclusivity or a newer supplemental NDA triggers exclusivity tied to clinical data.

Exclusivity mechanisms that can matter

5-year new chemical entity (usually not applicable to legacy PDE5 actives)
3-year new clinical investigations (sometimes applicable to line extensions or new dosing/label expansions)
7-year orphan (not broadly applicable to ED indications)

Why exclusivity is less central than lifecycle patents

For this class, patent-driven lifecycle is typically the dominant barrier compared with regulatory exclusivity for major branded lines.

Which PDE5 inhibitor combinations face unique patent barriers?

Featured snippet answer: The unique barrier is less about PDE5 inhibitors themselves and more about pairing compositions, fixed-dose combinations, or co-packaged regimens that introduce additional composition, formulation, and method-of-use claims.

Typical combination IP categories

fixed-dose combination compositions
dosage form patents for combination tablets
method-of-use claims for combined therapy strategies
manufacturing process patents tailored to co-dosing stability

How does PDE5 inhibitor manufacturing/IP barriers affect generic entry and supply?

Featured snippet answer: Manufacturing barriers are usually less about “impossible” processes and more about:

qualification of solid-state properties,
consistent dissolution and bioequivalence attributes,
avoiding process patents where relevant claims exist,
managing supply constraints that can prolong market entry even after legal barriers expire.

What controls bioequivalence risk

polymorph control and particle size distribution
tablet press parameters impacting dissolution
coating process reproducibility

How does the PDE5 inhibitor competitive landscape shape patent enforcement and licensing?

Featured snippet answer: Enforcement and licensing are calibrated to price pressure and formulary positioning. With heavy generic competition, brand holders concentrate on defending:

the product still showing meaningful margin,
the patent that most directly blocks the highest-volume strength,
territories where generic penetration lags.

Licensing as a substitute for litigation

When litigation cost outweighs incremental delay, licensors often use:

settlement-linked licenses
covenant structures allowing limited entry designs
regional licensing that monetizes remaining enforceable claims without global injunction risk

Key Takeaways

For PDE5 inhibitors, market exclusivity is now largely a lifecycle-patent story: formulation, manufacturing process, and method-of-use claims tied to specific dosing regimens and product strengths.
Patent expiration timing is less predictive than litigation and settlement practice for determining actual generic launch windows.
Orange Book status must be evaluated product-by-product; class-level conclusions do not map cleanly to launch risk.
FDA exclusivity is usually secondary for established PDE5 actives; most remaining delay is patent-driven.
Competitive economics drive enforcement selectivity and make licensing settlements common where generics can design around or where enforceability is uncertain.

FAQs

1) Do PDE5 inhibitor method-of-use patents block generic ANDA approval or only infringement?
Method-of-use patents can influence labeling and at-risk prescribing; infringement exposure depends on claim scope and labeling carve-outs, while ANDA approval hinges on statutory patent certifications and court outcomes.

2) Can generics launch immediately after patent expiry if a settlement stay exists?
No. Settlement-based covenants and court-enforced schedule terms can delay launch even when a particular patent expires, depending on the settlement’s date and scope.

3) Are polymorph or crystallinity patents a common barrier for PDE5 inhibitor generics?
Yes for the lifecycle layer in many solid oral classes; relevance depends on whether such patents remain listed and whether the generic formulation is designed to avoid them.

4) How do once-daily PDE5 dosing regimens change patent risk versus on-demand dosing?
Once-daily regimens often create distinct method-of-use and dosing-timing claim structures, which can increase the need for careful label positioning and formulation design.

5) What jurisdictions tend to be most important for PDE5 inhibitor profitability today?
Typically the largest reimbursement and prescribing markets where patent enforcement and generic launch timing materially affect net pricing and payer access, with country-level differences in patent linkage and register reliance.

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
FDA. (n.d.). Hatch-Waxman Amendments: Patent and Exclusivity. U.S. Food and Drug Administration.
US Court of Appeals for the Federal Circuit. (n.d.). Hatch-Waxman and ANDA litigation case law (relevant precedents). Federal Circuit.